Hypothesis

Psilocybin triggers a shallow, transient senescence program in microglia that releases a pro‑plasticity secretome (BDNF, IGF‑1, TGF‑β) and thereby enables the rapid, enduring remodeling of the default‑mode network (DMN) observed after psychedelic treatment. If this senescence‑dependent SASP is blocked or the senescent microglia are cleared, the antidepressant‑like effects of psilocybin will be attenuated.

Mechanistic Rationale

1. 5‑HT2A‑driven cell‑cycle checkpoint activation – Acute 5‑HT2A agonism elevates intracellular Ca2+ and activates the MAPK/ERK pathway, which can up‑regulate the cyclin‑dependent kinase inhibitor p21^Cip1/Waf1 without necessarily engaging the full p16^INK4a‑RB senescence axis. p21‑mediated arrest is known to produce a shallow senescence state characterized by a SASP enriched in growth factors rather than proinflammatory cytokines [1].
2. Microglia as plasticity modulators – Resting microglia surveil synapses and, upon activation, secrete BDNF and IGF‑1 that promote long‑term potentiation and dendritic spine formation [2]. A transient senescent shift could amplify this secretory bias, providing a temporally controlled burst of pro‑plastic signals.
3. Parallels with regenerative senescence – In salamander limb blastemas, senescence is induced, produces a regenerative SASP, and is subsequently cleared by macrophages [3]. A comparable cycle in the adult brain could allow psilocybin to hijack an evolutionarily conserved remodeling tool.
4. SASP depth matters – Chronic pathological senescence in aged glia expresses high p16, IL‑6, TNF‑α and impairs plasticity [4]. By contrast, a p21‑dominant, shallow state would avoid neuroinflammation while still delivering growth‑factor‑rich SASP.

Testable Predictions

• Prediction 1: Within 6‑24 h after a single psilocybin dose, a subset of Iba1+ microglia in the medial prefrontal cortex (mPFC) and hippocampus will show increased p21 (but not p16) protein and SA‑β‑gal activity, indicating shallow senescence.
• Prediction 2: Senescent microglia isolated at this time point will secrete elevated BDNF, IGF‑1, and TGF‑β, with minimal IL‑6/TNF‑α relative to microglia from saline‑treated controls or from aged mice exhibiting pathological senescence.
• Prediction 3: Genetic knockdown of p21 specifically in microglia (using Cx3cr1‑CreER; p21^fl/fl mice) or acute senolytic treatment (e.g., navitoclax) administered 2 h post‑psilocybin will blunt the psilocybin‑induced increase in BDNF levels and prevent the enduring (≈21‑day) increase in dendritic spine density in mPFC layer 2/3 neurons.
• Prediction 4: Behavioral assays of antidepressant‑like efficacy (e.g., reduced immobility in the forced swim test) will be attenuated in p21‑microglia knockout or senolytic‑treated mice compared with wild‑type controls receiving psilocybin.

Experimental Outline

1. Subjects: Adult male/female C57BL/6J mice (8‑10 weeks).
2. Treatment: Psilocybin (1 mg/kg, i.p.) or vehicle.
3. Time‑course: Harvest brains at 0, 6, 12, 24, 48 h, and 7 days for immunostaining (p21, p16, Iba1, SA‑β‑gal) and FACS sorting of microglia.
4. SASP profiling: ELISA or multiplex cytokine arrays on microglia‑conditioned media; focus on BDNF, IGF‑1, TGF‑β, IL‑6, TNF‑α.
5. Intervention groups: (a) Psilocybin + scrambled shRNA control; (b) Psilocybin + microglia‑specific p21 shRNA (AAV‑CX3CR1‑CreER delivering shRNA); (c) Psilocybin + navitoclax (100 mg/kg, i.p.) at 2 h; (d) Vehicle controls.
6. Readouts: (i) Western blot/IF for p21/p16; (ii) SASP ELISA; (iii) Golgi‑CoIm staining for spine density; (iv) forced swim and sucrose preference tests at day 21.

Falsifiability

If psilocybin does not induce a detectable increase in microglial p21 or shallow senescence markers, or if removing senescent microglia fails to alter BDNF release, spine remodeling, or behavioral outcomes, the hypothesis would be refuted. Conversely, confirmation would support the notion that psychedelics exploit a conserved senescence‑based remodeling mechanism, repositioning senescent cells from mere pathological byproducts to active negotiators of synaptic plasticity.